StreetInsider.com News Articles

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

March 11 (Reuters) - A ‌key U.S. federal vaccine advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post ‌reported on Wednesday, citing two people familiar with ⁠the matter.

Some vaccine advisers under Health and Human Services Secretary ‌Robert F. Kennedy Jr ‌had been seeking to potentially stop recommending mRNA shots, but that plan is no longer moving forward, the report said.

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

Form 4 Moderna, Inc. For: Mar 05 Filed by: Klinger Shannon Thyme

Fri, 06 Mar 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260306/26125841.html

Form 4 Moderna, Inc. For: Mar 05 Filed by: Klinger Shannon Thyme

Fri, 06 Mar 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260306/26125841.html

Form 4 Moderna, Inc. For: Mar 05 Filed by: Mock James M

Fri, 06 Mar 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260306/26125789.html

Form 4 Moderna, Inc. For: Mar 05 Filed by: Mock James M

Fri, 06 Mar 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260306/26125789.html

Form 8-K Moderna, Inc. For: Mar 03

Thu, 05 Mar 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260305/26114471.html

Form 8-K Moderna, Inc. For: Mar 03

Thu, 05 Mar 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260305/26114471.html

Moderna shares jump as settlement removes major legal overhang

Wed, 04 Mar 2026 08:36:50 -0400

Investing.com -- Moderna shares rose more than 9 percent premarket Tuesday after the company announced a global settlement that resolves all litigation with Arbutus Biopharma and Genevant Sciences related to its COVID-era vaccines.

Moderna said the agreement “provides certainty going forward” across its infectious disease portfolio, including candidates such as mNEXSPIKE and mCOMBRIAX, with no future royalties owed.

Under the settlement, Moderna will pay $950 million in the third quarter of 2026 and record the charge in the first quarter.

The company will also appeal the District Court’s Section 1498 ruling, arguing its government-contractor immunity limits

Moderna shares jump as settlement removes major legal overhang

Wed, 04 Mar 2026 08:36:50 -0400

Moderna said the agreement “provides certainty going forward” across its infectious disease portfolio, including candidates such as mNEXSPIKE and mCOMBRIAX, with no future royalties owed.

Under the settlement, Moderna will pay $950 million in the third quarter of 2026 and record the charge in the first quarter.

The company will also appeal the District Court’s Section 1498 ruling, arguing its government-contractor immunity limits

Moderna shares jump as settlement removes major legal overhang

Wed, 04 Mar 2026 08:36:50 -0400

Moderna said the agreement “provides certainty going forward” across its infectious disease portfolio, including candidates such as mNEXSPIKE and mCOMBRIAX, with no future royalties owed.

Under the settlement, Moderna will pay $950 million in the third quarter of 2026 and record the charge in the first quarter.

The company will also appeal the District Court’s Section 1498 ruling, arguing its government-contractor immunity limits

Moderna (MRNA) call put ratio 2.4 calls to 1 put into resolves litigation

Wed, 04 Mar 2026 05:27:13 -0400

Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 85; compared to its 52-week range of 54 to 105. Call put ratio 2.4 calls to 1 put into resolves litigation.

Jefferies Reiterates Hold Rating on Moderna (MRNA): "cash breakeven guidance is clearer"

Tue, 03 Mar 2026 17:15:39 -0400

Jefferies analyst Andrew Tsai reiterated a Hold rating and $37.00 price target on Moderna (NASDAQ: MRNA)

The analyst commented, "MRNA resolves a global patent litigation with ROIV/ABUS, agreeing to pay $950M upfront plus a pot'l payment of up to $1.3B (within 90 days of the Federal Circuit decision via Section 1498). We view the outcome as a (+) for MRNA, as $950M-$2.2B translates to an effective <2-5% royalty on $48B of cumulative WW sales - consistent with MRNA's messaging. Net-net, YE:26 cash guidance declines to $4.5-5.0B (from $5.5-6.0B), and 2028 cash breakeven guidance is clearer."

For an analyst ratings summary and ratings

After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more